Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Huntington Ingalls Industries Inc (HII) vs ResMed Inc. (RMD) Price & Performance

Huntington Ingalls Industries IncTrade
ResMed Inc.Trade

Price performance (Past 24H)

Key statistics

Huntington Ingalls Industries Inc vs ResMed Inc. — how do they compare? Huntington Ingalls Industries Inc trades at $326.59 (market cap $12.92B), while ResMed Inc. trades at $225 (market cap $32.61B). The key difference: ResMed Inc. is far larger — about 2.5× Huntington Ingalls Industries Inc's market cap, and Huntington Ingalls Industries Inc pays the higher dividend (1.68%). Which is the better fit depends on your goals.

HIIRMD
Market Cap
$12.92B$32.61B
Sector
TechnologyHealth
52-Week High
$453.73$293.73
52-Week Low
$265.40$182.82
Enterprise Value
$15.84B$31.97B
Dividend Yield
1.68%1.17%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Huntington Ingalls Industries Inc

HII trades at $328.43, down 0.72% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 results, beating EPS estimates with $5.27 versus $3.79 expected, and revenue growth of 10.9%. Recent news includes a $2.2 billion contract award for surveillance and intelligence capabilities, enhancing its defense portfolio. Valuation ratios show a P/E of 19.53 and P/S of 0.98, indicating reasonable pricing relative to earnings and sales.

Outlook is positive due to contract wins and operational improvements, but risks include political headwinds and execution challenges. Analyst consensus price target is $359.67, suggesting 9.5% upside. Investment opportunity lies in margin expansion from submarine contracts, while monitoring defense budget volatility is key.

ResMed Inc.

ResMed (RMD) trades at $226.00, up 2.7% with strong technical momentum and bullish moving averages. The company delivered three consecutive quarterly EPS beats, with Q4 2026 revenue growing 9% to $1.5 billion and non-GAAP EPS rising 16% to $2.95. Fundamentals show robust profitability with 26.94% net margin and 24.27% ROE, though weak 2027 revenue guidance has tempered sentiment.

Outlook remains positive with analyst consensus target of $235 offering 4% upside, but risks include ventilator sales suspension and cost pressures. The stock's current valuation at 21.56 P/E appears reasonable given strong cash flow generation and consistent dividend payments, making it attractive for growth-oriented healthcare investors despite near-term guidance concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Huntington Ingalls Industries Inc

Huntington Ingalls is the largest military shipbuilder in the U.S. and a provider of professional services to government and industry partners, specializing in nuclear-powered submarines and aircraft carriers.

Read more on HII

About ResMed Inc.

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

Read more on RMD